Stock info Eli Lilly | Filter Basic-Info
Stock: Eli Lilly (US broad), ISIN: US5324571083
| Last Price | 750.77 | Max Price | 782.06 |
| Min Price | 369.91 | 1 Year return | 105.22 |
| Sector | Health Care | Subsector | Pharmaceuticals |
| Annual report 2017 |
Contact info:Street: Lilly Corporate CenterZip Code: 46285City: IndianapolisCountry: USAPhone: 3172762000Website: www.lilly.comCEO: John C. LechleiterCFO: Derica W. Rice
Sector Review Eli Lilly
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 22,320 | 615,634 | 3.63 % |
| 2020 | 24,540 | 638,070 | 3.85 % |
| 2021 | 28,318 | 727,968 | 3.89 % |
| 2022 | 28,541 | 787,273 | 3.63 % |
| 2023 | 0 | 0 | 0.00 % |
Advice Eli Lilly
No Records Found
News Eli Lilly
Analysts: more sales Eli Lilly
Analysts expect over 2021 rising revenue Eli Lilly
Lilly's migraine med approved in Canada for episodic cluster headache
Eli Lilly Partners with Blacksmith Medicines in $300mn Seed Funding Deal
Eli Lilly huge outperformer in American pharmaceutical sector
Annual reports Eli Lilly
| 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
Profile Eli Lilly
Lilly (Eli) & Co.
(US5324571083)/ LLYThe past year was a relatively good year for Lilly (Eli) & Co. investors
The stock lost over the past 12 months at around 15 percent. Over the period from December 2011 till December 2016 the stock rose on average 77 percent. Lilly (Eli) & Co. 's revenues between 2011 and 2015 were quite similar and moved between 22,6 billion dollars and 19,96 billion dollars. The net results between 2011 and 2015 were far from constant and fluctuated between 4,35 billion dollars and 2,41 billion dollars.
Lilly (Eli) & Co. 's head office is based in Indianapolis. Lilly (Eli) & Co. 's core business is the pharmaceutical sector. John C. Lechleiter is operating by ' CEO. Derica W. Rice is financially responsible for the company as CFO. The past 10 years the (international) industry gained at around 75 percent. Over the past 5 years the sector is 147 percent higher.
Over the past 5 years the American company paid out dividends. On average the Lilly (Eli) & Co. stock yielded a delivered a dividend yield of around 9,86 percent over the past 5 years. Over the past 5 years Lilly (Eli) & Co. raised her dividends share each year. Based on the raising dividend payments Lilly (Eli) & Co. can be seen as a kind of dividend aristocrat.
Lilly (Eli) & Co. financed with relatively low debt
At the end of 2015 the pharmaceutical company's balance sheet equaled 35,57 billion dollars. Last year the total debt of the company was 21 billion dollars. This equals around 59,03 percent of the total balance sheet. The American company's price/earnings-ratio was 21. So the market valued the stock at 21 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 92,01 billion dollars. At the end of 2015 around 1,11 billion stocks were listed.
All the annual reports of Lilly (Eli) & Co. are available here. More information about Lilly (Eli) & Co. can be found it's website. .
Results Eli Lilly
| Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Revenue |
19,959
|
21,222
|
22,871
|
24,556
|
22,320
|
24,540
|
| Costs |
17,550
|
18,485
|
23,075
|
21,324
|
14,001
|
18,346
|
| Profit |
2,408
|
2,738
|
-204
|
3,232
|
8,318
|
6,194
|
| Margin of profit |
12.07
|
12.90
|
-0.89
|
13.16
|
37.27
|
25.24
|
| ROI |
16.53
|
19.54
|
-1.76
|
32.88
|
319.09
|
109.79
|
Balance Eli Lilly
| Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Equity |
14,571
|
14,008
|
11,592
|
9,829
|
2,607
|
5,642
|
| Debt |
20,998
|
24,798
|
33,389
|
34,080
|
36,679
|
40,992
|
| Total assets |
35,569
|
38,806
|
44,981
|
43,908
|
39,286
|
46,633
|
| Solvency |
40.97
|
36.10
|
25.77
|
22.38
|
6.64
|
12.10
|
| Cash |
4,452
|
6,039
|
8,034
|
7,409
|
2,439
|
3,681
|
| Cashflow |
2,965
|
4,851
|
5,616
|
5,525
|
4,837
|
6,500
|
| Employees |
0
|
0
|
0
|
0
|
0
|
|
| Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow / Debt |
0.14
|
0.20
|
0.17
|
0.16
|
0.13
|
0.16
|
Details Eli Lilly
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
84.26
|
73.55
|
84.46
|
115.72
|
131.43
|
| Eps |
2.58
|
-0.19
|
3.13
|
8.89
|
6.79
|
| Price/earnings-ratio |
32.66
|
-387.11
|
26.98
|
13.02
|
110.57
|
| Dividend |
2.04
|
2.08
|
2.25
|
2.58
|
2.96
|
| Dividend % |
2.42 %
|
2.83 %
|
2.66 %
|
2.23 %
|
0.39 %
|
| Payout % |
0.79
|
-10.95
|
0.72
|
0.29
|
0.44
|
| Book value |
12.72
|
10.54
|
9.29
|
2.72
|
5.90
|
| Market to book |
0.15
|
0.14
|
0.11
|
0.02
|
0.01
|
| Cashflow per stock |
4.41
|
5.11
|
5.22
|
5.05
|
6.79
|
| Stocks |
1,101
|
1,100
|
1,058
|
958
|
957
|
| Market Cap |
92.759.73
|
80.905.59
|
89.328.27
|
110.804.91
|
718.179.07
|
Dividend Eli Lilly
Price info Eli Lilly
|
Date
|
Price
|
|---|---|
|
18 Apr 2024
|
750.77
|
|
17 Apr 2024
|
746.74
|
|
09 Apr 2024
|
757.24
|
|
05 Apr 2024
|
768.08
|
|
03 Apr 2024
|
763.96
|
|
30 Mar 2024
|
777.96
|
|
22 Mar 2024
|
770.26
|
|
18 Mar 2024
|
762.66
|
|
15 Mar 2024
|
760.73
|
|
12 Mar 2024
|
734.37
|
|
11 Mar 2024
|
762.14
|
|
09 Mar 2024
|
762.14
|
|
07 Mar 2024
|
779.77
|
|
01 Mar 2024
|
753.68
|
|
29 Feb 2024
|
757.64
|
|
27 Feb 2024
|
771.92
|
|
22 Feb 2024
|
745.91
|
|
21 Feb 2024
|
755.66
|
|
20 Feb 2024
|
782.06
|
|
15 Feb 2024
|
757.31
|
|
14 Feb 2024
|
742.97
|
|
13 Feb 2024
|
737.26
|
|
09 Feb 2024
|
735.68
|
|
08 Feb 2024
|
725.38
|
|
07 Feb 2024
|
705.03
|
|
06 Feb 2024
|
706.20
|
|
05 Feb 2024
|
667.65
|
|
01 Feb 2024
|
645.61
|
|
31 Jan 2024
|
644.98
|
|
30 Jan 2024
|
645.00
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
